Citadel Advisors’s Candel Therapeutics CADL Stock Holding History

Citadel Advisors’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$637K	Buy	+61,800	New	+$467K	﹤0.01%	9304
2026 Q1	–	Sell	-21,400	Closed	-$121K	–	13064
2025 Q4	$121K	Sell	21,400 -11,900	-36%	-$64K	﹤0.01%	11490
2025 Q3	$170K	Sell	33,300 -4,300	-11%	-$24.8K	﹤0.01%	11429
2025 Q2	$190K	Sell	37,600 -10,300	-22%	-$53K	﹤0.01%	10723
2025 Q1	$271K	Sell	47,900 -66,600	-58%	-$544K	﹤0.01%	9818
2024 Q4	$994K	Buy	114,500 +88,900	+347%	+$525K	﹤0.01%	7037
2024 Q3	$177K	Buy	25,600 +11,300	+79%	+$70.2K	﹤0.01%	10321
2024 Q2	$88.7K	Buy	+14,300	New	+$107K	﹤0.01%	11084

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's CADL Position: Q2 2026 in Review

Citadel Advisors increased its Candel Therapeutics (CADL) stake by 101% in Q2 2026, buying an estimated $554K and bringing the position to 146,016 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #7206.

Citadel Advisors first reported a position in CADL in Q3 2022 and has held it in 11 quarters since. The position peaked at $2.53M in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Citadel Advisors held 146,016 shares of Candel Therapeutics worth $1.5M as of Q2 2026.
Citadel Advisors bought 73,350 Candel Therapeutics shares in Q2 2026, an estimated $554K.
Candel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7206 holding.
Citadel Advisors first reported a position in Candel Therapeutics in Q3 2022 and has held it in 11 quarters since.
Citadel Advisors's Candel Therapeutics position peaked at $2.53M in Q4 2024.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.